To Dance or not to Dance: Biosimilar Strategies Post Amgen v Sandoz

December 3, 2015Articles Life Sciences Intellectual Property Review

The Biologics Price Competition and Innovation Act (BPCIA) is a landmark piece of legislation signed into law by the Obama administration in 2009. The BPCIA provides for a regulatory approval pathway for biosimilar products, which are like generic pharmaceuticals in that they are based on already approved ‘name brand’ biologics.

Click here to access full article